Innoviva, Inc. INVA

BURLINGAME, Calif., September 02, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:

WALTHAM, Mass., August 11, 2026--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics produ

Innoviva, Inc. reported second-quarter 2026 results showing revenue of US$119.59 million, up from US$100.28 million a year earlier, but it moved from a net income of US$63.69 million to a net loss of US$83.42 million. Alongside these mixed earnings, Innoviva completed a substantial share repurchase under its November 2025 authorization, buying back 3,055,966 shares for US$66.40 million, which may reshape how investors view its capital allocation priorities. We’ll now examine how Innoviva’s...

BURLINGAME, Calif., August 05, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2026, and highlighted select corporate progress and achievements.

Innoviva, Inc. (NASDAQ:INVA) is one of the best cheap small cap stocks to buy now. Nortiva Bio, Inc., which is a wholly owned subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced on June 18 its launch as a clinical-stage biopharmaceutical company dedicated to the development of long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Innoviva, Inc. […]

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Innoviva, Inc. (NASDAQ:INVA) is one of the most promising stocks on our list. TheFly reported on June 18 that INVA announced the launch of Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral therapies through its proprietary […]

Innoviva Inc. (NASDAQ:INVA) is one of the most profitable undervalued stocks to invest in. On June 16, Innoviva Specialty Therapeutics entered an exclusive licensing and distribution agreement with Dr. Reddy’s Laboratories to bring XACDURO to South and Central America, the Caribbean, Russia, and the CIS region. The partnership aims to address a critical health challenge, […]

LEXINGTON, Mass., June 18, 2026--Nortiva Bio, Inc. ("Nortiva") today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva’s LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can optimize efficacy and safety, improve medication adherence, and positively impact pat